Free Trial

Monte Rosa Therapeutics (GLUE) SEC Filings & 10K Form

Monte Rosa Therapeutics logo
$7.74 -0.74 (-8.73%)
(As of 11/15/2024 ET)

Recent Monte Rosa Therapeutics SEC Filings

DateFilerForm TypeView
11/07/2024
6:02 AM
Monte Rosa Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/07/2024
6:07 AM
Monte Rosa Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/30/2024
4:10 PM
Monte Rosa Therapeutics (Subject)
Versant Venture Capital VI, L.P. (Filed by)
Form SC 13D/A
10/28/2024
3:05 PM
Monte Rosa Therapeutics (Subject)
Wallace Owen B. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/28/2024
5:59 AM
Monte Rosa Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/24/2024
4:00 PM
Monte Rosa Therapeutics (Subject)
Versant Venture Capital VI, L.P. (Filed by)
Form SC 13D/A
09/24/2024
3:40 PM
Monte Rosa Therapeutics (Issuer)
Versant Vantage I GP, L.P. (Reporting)
Versant Vantage I GP-GP, LLC (Reporting)
Versant Vantage I, L.P. (Reporting)
Versant Venture Capital VI, L.P. (Reporting)
Versant Ventures VI GP, L.P. (Reporting)
Versant Ventures VI GP-GP, LLC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2024
5:44 PM
Monte Rosa Therapeutics (Issuer)
Versant Vantage I GP, L.P. (Reporting)
Versant Vantage I GP-GP, LLC (Reporting)
Versant Vantage I, L.P. (Reporting)
Versant Venture Capital VI, L.P. (Reporting)
Versant Ventures VI GP, L.P. (Reporting)
Versant Ventures VI GP-GP, LLC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/13/2024
3:30 PM
Janku Filip (Reporting)
Monte Rosa Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2024
6:46 PM
Monte Rosa Therapeutics (Subject)
New Enterprise Associates 17, L.P. (Filed by)
Form SC 13D/A
08/12/2024
4:07 PM
Monte Rosa Therapeutics (Subject)
Versant Venture Capital VI, L.P. (Filed by)
Form SC 13D/A
08/08/2024
6:02 AM
Monte Rosa Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/08/2024
6:04 AM
Monte Rosa Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/09/2024
3:15 PM
Dunn Edmund (Reporting)
Monte Rosa Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2024
6:04 AM
Monte Rosa Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/13/2024
7:12 PM
Behbahani Ali (Reporting)
Monte Rosa Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/30/2024
6:18 AM
Monte Rosa Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/13/2024
7:40 PM
Monte Rosa Therapeutics (Subject)
New Enterprise Associates 17, L.P. (Filed by)
Form SC 13D/A
05/09/2024
6:45 AM
Monte Rosa Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/09/2024
6:05 AM
Monte Rosa Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/10/2024
3:24 PM
Jones Jullian G (Reporting)
Monte Rosa Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/10/2024
11:58 AM
Monte Rosa Therapeutics (Subject)
PRICE T ROWE ASSOCIATES INC /MD/ (Filed by)
Form SC 13G/A
03/14/2024
6:44 AM
Monte Rosa Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/14/2024
6:05 AM
Monte Rosa Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2024
10:22 AM
BlackRock Inc. (Filed by)
Monte Rosa Therapeutics (Subject)
Form SC 13G/A
02/14/2024
8:14 AM
Avoro Capital Advisors LLC (Filed by)
Monte Rosa Therapeutics (Subject)
Form SC 13G/A
02/09/2024
8:28 AM
FMR LLC (Filed by)
Monte Rosa Therapeutics (Subject)
Form SC 13G/A
01/08/2024
6:47 AM
Monte Rosa Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/04/2024
3:15 PM
Monte Rosa Therapeutics (Issuer)
Nickson Philip (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:15 PM
Dunn Edmund (Reporting)
Monte Rosa Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:15 PM
Janku Filip (Reporting)
Monte Rosa Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:15 PM
Jones Jullian G (Reporting)
Monte Rosa Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:15 PM
Monte Rosa Therapeutics (Issuer)
Wallace Owen B. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:15 PM
Monte Rosa Therapeutics (Issuer)
Warmuth Markus (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:GLUE) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners